Literature DB >> 18794650

A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.

Hiroyoshi Takeuchi1, Takefumi Suzuki, Hiroyuki Uchida, Shinichiro Nakajima, Kensuke Nomura, Toshiaki Kikuchi, Hiroshi Manki, Koichiro Watanabe, Haruo Kashima.   

Abstract

Although recent treatment guidelines for schizophrenia recommend that the prior antipsychotic agent should remain stable for at least 2 weeks when aripiprazole is introduced, there is no trial-based evidence to support this strategy. This study was designed to compare this strategy with another conventional one in patients with schizophrenia. We conducted a randomized, 14-week, open-label trial to compare the following 2 switching strategies: (1) add-on of aripiprazole on a current regimen, wait for 4 weeks, and the tapering of prior antipsychotics and (2) add-on of aripiprazole and the simultaneous tapering of prior antipsychotics in patients with schizophrenia. Aripiprazole was initiated at 12 mg/d and then titrated between 12 and 30 mg. The previous antipsychotic medication was reduced biweekly by 25%. Assessments included the Clinical Global Impression Scale Schizophrenia version, the Drug-Induced Extrapyramidal Symptoms Scale, and the Subjective Well-being Under Neuroleptics, Short Version, Japanese Edition. Impressions toward their assigned strategy were also subjectively evaluated at baseline and end point. Fifty-three patients were enrolled, and 48 patients completed this trial. No significant differences were found in changes from the baseline in the total Clinical Global Impression Scale Schizophrenia version severity, Drug-Induced Extrapyramidal Symptoms Scale, and Subjective Well-being Under Neuroleptics, Short Version, Japanese Edition scores throughout the study period between the 2 strategies. Both strategies were judged by subjects to be tolerable and favorable without between-group differences. In conclusion, both strategies were found to be objectively safe and well tolerated. Taken together with similar results from subjective assessments, it would be reasonable to choose either of these 2 strategies in clinical practice based on a patients' preference.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794650     DOI: 10.1097/JCP.0b013e3181842586

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  10 in total

Review 1.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 2.  Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients.

Authors:  Jeffrey Rado; Philip G Janicak
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

Review 3.  Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis.

Authors:  Hiroyoshi Takeuchi; Navot Kantor; Hiroyuki Uchida; Takefumi Suzuki; Gary Remington
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

4.  Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study.

Authors:  Chi-Un Pae; Alberto Chiesa; Laura Mandelli; Ashwin A Patkar; Sara Gibiino; Alessandro Serretti
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

5.  Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis.

Authors:  Zhe Lu; Yaoyao Sun; Yuyanan Zhang; Yu Chen; Liangkun Guo; Yundan Liao; Zhewei Kang; Xiaoyang Feng; Weihua Yue
Journal:  Transl Psychiatry       Date:  2022-07-05       Impact factor: 7.989

Review 6.  Aripiprazole for late-life schizophrenia.

Authors:  Jeffrey Rado; Philip G Janicak
Journal:  Clin Interv Aging       Date:  2010-09-07       Impact factor: 4.458

7.  Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole.

Authors:  Yoshiaki Obayashi; Satoshi Mitsui; Shinji Sakamoto; Nozomu Minao; Bunta Yoshimura; Toshiki Kono; Yuji Yada; Yuko Okahisa; Soshi Takao; Yoshiki Kishi; Toshihiko Takeda; Manabu Takaki; Norihito Yamada
Journal:  Psychopharmacology (Berl)       Date:  2019-10-18       Impact factor: 4.530

Review 8.  Aripiprazole versus other atypical antipsychotics for schizophrenia.

Authors:  Priya Khanna; Tao Suo; Katja Komossa; Huaixing Ma; Christine Rummel-Kluge; Hany George El-Sayeh; Stefan Leucht; Jun Xia
Journal:  Cochrane Database Syst Rev       Date:  2014-01-02

9.  Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis.

Authors:  Dan Siskind; Erin Gallagher; Karl Winckel; Samantha Hollingworth; Steve Kisely; Joseph Firth; Christoph U Correll; Wade Marteene
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

Review 10.  TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel.

Authors:  Baybars Veznedaroglu; Nesrin Dilbaz; Ozcan Uzun; Erdal Isik
Journal:  Ther Adv Psychopharmacol       Date:  2018-05-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.